These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12023799)

  • 1. Modeling the epidermal growth factor -- epidermal growth factor receptor l2 domain interaction: implications for the ligand binding process.
    Jorissen RN; Treutlein HR; Epa VC; Burgess AW
    J Biomol Struct Dyn; 2002 Jun; 19(6):961-72. PubMed ID: 12023799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor.
    Jorissen RN; Epa VC; Treutlein HR; Garrett TP; Ward CW; Burgess AW
    Protein Sci; 2000 Feb; 9(2):310-24. PubMed ID: 10716183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor alpha.
    Reddy CC; Wells A; Lauffenburger DA
    J Cell Physiol; 1996 Mar; 166(3):512-22. PubMed ID: 8600155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand binding characterization and molecular analysis of distinct epidermal growth factor-urogastrone receptors in cultured smooth muscle and epithelial cells from guinea pig intestine.
    Yang SG; Ahmad S; Wong NC; Hollenberg MD
    Mol Pharmacol; 1994 Aug; 46(2):256-65. PubMed ID: 8078489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer?
    Groenen LC; Walker F; Burgess AW; Treutlein HR
    Biochemistry; 1997 Apr; 36(13):3826-36. PubMed ID: 9092812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity.
    Iyer AK; Tran KT; Borysenko CW; Cascio M; Camacho CJ; Blair HC; Bahar I; Wells A
    J Cell Physiol; 2007 Jun; 211(3):748-58. PubMed ID: 17311283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-function studies of ligand-induced epidermal growth factor receptor dimerization.
    Neelam B; Richter A; Chamberlin SG; Puddicombe SM; Wood L; Murray MB; Nandagopal K; Niyogi SK; Davies DE
    Biochemistry; 1998 Apr; 37(14):4884-91. PubMed ID: 9538006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The coupling between transforming growth factor-alpha and the epidermal growth factor receptor during rat liver regeneration.
    Strömblad S; Andersson G
    Exp Cell Res; 1993 Feb; 204(2):321-8. PubMed ID: 8440328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of dimerization and enzymatic activity of epidermal growth factor receptor in the absence of epidermal growth factor.
    Tanner KG
    Biochemistry; 1997 Dec; 36(48):14889-96. PubMed ID: 9398212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations within subdomain II of the extracellular region of epidermal growth factor receptor selectively alter TGF alpha binding.
    Harte MT; Gentry LE
    Arch Biochem Biophys; 1995 Oct; 322(2):378-89. PubMed ID: 7574711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemical synthesis and binding affinity to the EGF receptor of the EGF-like domain of heparin-binding EGF-like growth factor (HB-EGF).
    Shin SY; Yokoyama T; Takenouchi T; Munekata E
    J Pept Sci; 2003 Apr; 9(4):244-50. PubMed ID: 12725245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor receptors: structure, mechanism, and drug discovery.
    McInnes C; Sykes BD
    Biopolymers; 1997; 43(5):339-66. PubMed ID: 9566117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of epidermal growth factor receptor by epidermal growth factor.
    Sherrill JM; Kyte J
    Biochemistry; 1996 May; 35(18):5705-18. PubMed ID: 8639530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine transforming growth factor alpha is dispensible for v-rasHa-induced epidermal neoplasia: potential involvement of alternate epidermal growth factor receptor ligands.
    Dlugosz AA; Cheng C; Williams EK; Darwiche N; Dempsey PJ; Mann B; Dunn AR; Coffey RJ; Yuspa SH
    Cancer Res; 1995 May; 55(9):1883-93. PubMed ID: 7728756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the epidermal growth factor receptor: a series of twists and turns.
    Poger D; Mark AE
    Biochemistry; 2014 Apr; 53(16):2710-21. PubMed ID: 24697572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
    Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
    Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay.
    Barta P; Volkova M; Dascalu A; Spiegelberg D; Trejtnar F; Andersson K
    J Pharmacol Toxicol Methods; 2014; 70(2):145-51. PubMed ID: 25084055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.